For the third consecutive year, Shippy's Rolling Plains Construction will serve as a primary sponsor for Ryan Ellis’ No. 71 ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...